Clinical Trials Directory

Trials / Completed

CompletedNCT01394458

Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution: A Pilot Study

Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution to Prevent Hemodialysis Catheter-Related Infections: A Pilot Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
University of Manitoba · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Currently in Canada, either 4% sodium citrate or heparin 1,000-10,000 U/ml solutions are "locked" into hemodialysis catheters between dialysis sessions to prevent thrombosis. The use of an ethanol/sodium citrate locking solution may have advantages over either of these agents alone. The investigators hypothesize that the 30 % ethanol/4% sodium citrate catheter locking solution is safe and effective in the prevention of catheter-related infections and thrombosis.

Detailed description

The pilot study will utilize a prospective, randomized design. After meeting the inclusion/exclusion criteria and providing written informed consent, patients will be randomly assigned to a 30 % ethanol/ 4% sodium citrate locking solution or heparin 1000 U/ml. Patients will be enrolled from the Health Sciences Centre and the Sherbrook Dialysis Units in Winnipeg, Manitoba, Canada.

Conditions

Interventions

TypeNameDescription
OTHER30 % ethanol / 4% sodium citrate catheter locking solutionThis solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.
DRUGHeparin 1000 u / mlIn the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.

Timeline

Start date
2011-08-01
Primary completion
2013-11-01
Completion
2013-11-01
First posted
2011-07-14
Last updated
2015-12-04

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01394458. Inclusion in this directory is not an endorsement.